Pancreatic Endocrine Tumor - Pipeline Review, H2 2015
Summary
Global Markets Directs, Pancreatic Endocrine Tumor - Pipeline Review, H2 2015, provides an overview of the Pancreatic Endocrine Tumors therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Pancreatic Endocrine Tumor, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pancreatic Endocrine Tumor and special features on late-stage and discontinued projects.
Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Pancreatic Endocrine Tumor
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Pancreatic Endocrine Tumor and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Pancreatic Endocrine Tumor products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Pancreatic Endocrine Tumor pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Pancreatic Endocrine Tumor
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Pancreatic Endocrine Tumor pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table Of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Pancreatic Endocrine Tumor Overview 6
Therapeutics Development 7
Pipeline Products for Pancreatic Endocrine Tumor - Overview 7
Pipeline Products for Pancreatic Endocrine Tumor - Comparative Analysis 8
Pancreatic Endocrine Tumor - Therapeutics under Development by Companies 9
Pancreatic Endocrine Tumor - Pipeline Products Glance 10
Late Stage Products 10
Clinical Stage Products 11
Early Stage Products 12
Pancreatic Endocrine Tumor - Products under Development by Companies 13
Pancreatic Endocrine Tumor - Companies Involved in Therapeutics Development 14
Ipsen S.A. 14
Jiangsu Hengrui Medicine Co., Ltd. 15
MediaPharma s.r.l. 16
Novartis AG 17
Tyrogenex, Inc. 18
Pancreatic Endocrine Tumor - Therapeutics Assessment 19
Assessment by Monotherapy Products 19
Assessment by Target 20
Assessment by Mechanism of Action 22
Assessment by Route of Administration 24
Assessment by Molecule Type 26
Drug Profiles 28
lanreotide acetate - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
MPHE-001B - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
pasireotide LAR - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
SHR-1020 - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
X-82 - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Pancreatic Endocrine Tumor - Recent Pipeline Updates 37
Pancreatic Endocrine Tumor - Discontinued Products 42
Pancreatic Endocrine Tumor - Product Development Milestones 43
Featured News & Press Releases 43
Oct 15, 2015: Ipsen Announces Eight Studies of Somatuline Depot (lanreotide) in Gastroenteropancreatic Neuroendocrine Tumors Being Presented at the North American Neuroendocrine Tumor Society Symposium 43
Oct 06, 2015: Health Canada Approves Somatuline Autogel (lanreotide) Injection for the treatment of enteropancreatic neuroendocrine tumours 44
May 14, 2015: Ipsen Announces Data Presentations for Somatuline Depot (lanreotide) in Gastroenteropancreatic Neuroendocrine Tumors at American Society of Clinical Oncology Annual Meeting 44
Apr 14, 2015: MHRA approves Ipsen’s Somatuline (lanreotide) Autogel 120mg as a new treatment for gastroenteropancreatic tumours 45
Jan 13, 2015: Ipsen Biopharmaceuticals to Present Further Data on Recently FDA-Approved Antitumor Therapy, Somatuline Depot (lanreotide), at Gastrointestinal Cancers Symposium 46
Dec 16, 2014: Ipsen’s Somatuline Depot is the first therapy approved by the FDA in the United States for the treatment of patients with locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors 46
Appendix 48
Methodology 48
Coverage 48
Secondary Research 48
Primary Research 48
Expert Panel Validation 48
Contact Us 48
Disclaimer 49
List Of Tables
Number of Products under Development for Pancreatic Endocrine Tumor, H2 2015 7
Number of Products under Development for Pancreatic Endocrine Tumor - Comparative Analysis, H2 2015 8
Number of Products under Development by Companies, H2 2015 9
Comparative Analysis by Late Stage Development, H2 2015 10
Comparative Analysis by Clinical Stage Development, H2 2015 11
Comparative Analysis by Early Stage Development, H2 2015 12
Products under Development by Companies, H2 2015 13
Pancreatic Endocrine Tumor - Pipeline by Ipsen S.A., H2 2015 14
Pancreatic Endocrine Tumor - Pipeline by Jiangsu Hengrui Medicine Co., Ltd., H2 2015 15
Pancreatic Endocrine Tumor - Pipeline by MediaPharma s.r.l., H2 2015 16
Pancreatic Endocrine Tumor - Pipeline by Novartis AG, H2 2015 17
Pancreatic Endocrine Tumor - Pipeline by Tyrogenex, Inc., H2 2015 18
Assessment by Monotherapy Products, H2 2015 19
Number of Products by Stage and Target, H2 2015 21
Number of Products by Stage and Mechanism of Action, H2 2015 23
Number of Products by Stage and Route of Administration, H2 2015 25
Number of Products by Stage and Molecule Type, H2 2015 27
Pancreatic Endocrine Tumor Therapeutics - Recent Pipeline Updates, H2 2015 37
Pancreatic Endocrine Tumor - Discontinued Products, H2 2015 42
List Of Figures
Number of Products under Development for Pancreatic Endocrine Tumor, H2 2015 7
Number of Products under Development for Pancreatic Endocrine Tumor - Comparative Analysis, H2 2015 8
Number of Products under Development by Companies, H2 2015 9
Comparative Analysis by Clinical Stage Development, H2 2015 11
Assessment by Monotherapy Products, H2 2015 19
Number of Products by Top 10 Targets, H2 2015 20
Number of Products by Stage and Top 10 Targets, H2 2015 20
Number of Products by Top 10 Mechanism of Actions, H2 2015 22
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015 22
Number of Products by Top 10 Routes of Administration, H2 2015 24
Number of Products by Stage and Top 10 Routes of Administration, H2 2015 24
Number of Products by Top 10 Molecule Types, H2 2015 26
Number of Products by Stage and Top 10 Molecule Types, H2 2015 26
